Biotech Next Gen 2021 has ended
Back To Schedule
Wednesday, June 23 • 10:25am - 10:50am
The New Path to Market for Emerging Biotech

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk. This session will explore new commercial realities and considerations for how to reduce risk, manage costs and optimize performance while maintaining control of your asset.

avatar for Lee Taurman

Lee Taurman

Executive Managing Director and Global Head, Commercial Innovation and Solutions, Syneos Health
Lee Taurman is an experienced Life Sciences industry executive and management consultant.  He specializes in working with clients to develop innovative solutions as they evolve to meet the needs of a changing healthcare and business landscape.    This includes developing new integrated... Read More →

Wednesday June 23, 2021 10:25am - 10:50am EDT